Pioneering Extracellular
Protein Degradation

Transcera is pioneering a new class of therapeutics that harness natural lipid trafficking pathways to direct proteins into lysosomes for degradation. Our approach combines a proprietary lysosome-targeting lipid, tunable chemical linker, and peptide or protein binder into a compact, manufacturable molecule that can degrade diverse extracellular targets – including soluble and membrane proteins – across tissues and cell types. By enabling potent, selective, and systemic degradation, Transcera’s platform opens new possibilities for treating chronic diseases driven by aberrant extracellular biology.